Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Introduction

Memory loss is the most common complaint of women going through the phases of menopause (1), and the postmenopausal memory decline might be associated with reduced ovary functions, which lead to depletion of ovarian hormones such as estrogen (2, 3). Accordingly,
estrogen or hormone replacement therapy has been shown to improve cognitive function in postmenopausal women (4–7). However, compliance with long-term treatment with estrogen for menopausal women is poor because of side effects. In addition, the Women’s Health Initiative Memory Study reported that hormone replacement therapy increased the risk of developing memory deficits in postmenopausal women of 65 years of age or older (8, 9). Therefore, the development of safer and more effective drug therapies has been strongly anticipated by postmenopausal women with memory deficits.

Placenta contains a great variety of bioactive molecules, such as hepatocyte growth factor (10), nerve growth factor (11), epidermal growth factor (12), fibroblast growth factor (13), insulin-like growth factors (14), and transforming growth factors (15, 16), as well as estrogens (17, 18), and has growth-promoting activity. In fact, the extract of human placenta has been used as a traditional folk remedy in many Asian countries for the treatment of liver diseases and skin disorders (19). In addition, a recent randomized clinical trial demonstrated that chronic treatment of human placental extract improved some menopausal symptoms and fatigue in middle-aged women (20). However, the clinical benefits of placenta therapy for menopausal symptoms and the effects against menopausal memory decline remain unclear.

We have recently found that combination of ovariectomy (OVX) and chronic restraint stress (CS) causes memory impairment and reduces hippocampal CA3 neurons in female rodents and that estrogen treatment suppresses the CS-induced behavioral and morphological changes (21, 22). That is, we have revealed that CS-subjected OVX animals can be considered as a useful model of postmenopausal memory deficits. In this study, we examined the effects of chronic treatment of porcine placental extract on CS-induced behavioral, neurochemical, and tissue changes in OVX female mice. After chronic stress, conditioned fear performance was tested. Following the behavioral test, hippocampal cell density, bone mineral density, and uterine weight were evaluated.

Materials and Methods

Materials

Bulk powder of JPB Porcine 100 (Lot No. P-60701; Japan Bio Products Co., Ltd., Tokyo) was used for placental extract administration. According to the product information provided by the company, the bulk powder of placental extract is produced as follows: the Japanese domestic porcine (Sus scrofa domesticus) placentae are treated with protease and heat sterilization, and then the resulting extract is freeze-dried and ground. The resulting placental extract is assumed to contain estrogenic hormones, growth factors, and other biologically active substances. Generally, for clinical use, one ampule including 112 mg of human placental extract can be used per day per person by intramuscular or subcutaneous injection. In this study, the proper oral dosage was calculated to be 120 mg/kg with reference to one ampule for a 60 kg human, using the formula for dose translation based on body surface area (23). In accordance with previous animal studies (24, 25), the present study was further designed to examine the effect of a high dose of placental extract (2160 mg/kg).

Animals and treatments

Two cohorts initially totaling 47 female ICR mice (Japan SLC, Inc., Hamamatsu), age 8–9 weeks, weighing 26–33 g at the beginning of the experiments, were used. They were housed 4–6 per cage under standard light-dark conditions (12-h light cycle starting at 8:45 h) at a constant temperature of 23°C ± 1°C. The animals had free access to food and water and they were handled in accordance with the guidelines established by the Institutional Animal Care and Use Committee of Kanazawa University, the Guiding Principles for the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society, and the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals.

One week after arrival, a quarter of the experimental animals underwent sham operation and the rest of them were bilaterally ovariectomized (OVX) under pentobarbital (40 mg/kg) anesthesia. From the next day of surgical operation, OVX animals were randomly divided into three groups (group 1–3), and then the animals of group 1 and group 2 were orally administered with placental extract at 120 and 2160 mg/kg, respectively, once daily to the end of behavioral analysis. The OVX mice of group 3 and sham-operated mice were orally treated with vehicle (distilled water) for 5 weeks before the behavioral analysis. Body weight of each mouse was measured before drug treatment and recorded every day.

Immobilization stress began 2 weeks after the operation and was repeated every day for 3 consecutive weeks. The stress was performed with a stainless mesh that allowed for a close fit to mice for 6 h (between 9:00 am and 3:00 pm) (21, 22, 26, 27) in their home cages. Sham-operated animals were not subjected to stress (No stress group), but were handled at 9:00 am for a few seconds. Following the repeated restraint stress for 3 weeks, behavioral analysis was performed and then mice were killed for histochemical and morphological analyses.
Contextual fear conditioning test
The day after the stress period, a mouse was placed in a plastic cage (25 × 31 × 18 cm), and the freezing response was measured for 1 min in the absence of sound (pre-tone phase). Each mouse was placed in an acrylic cage (31 × 31 × 40 cm) equipped with stainless grids (2 mm diameter, 6 mm pitch) and was allowed to explore the cage freely for 2 min (pre-conditioned phase), and then a 20-s tone (80 dB) was delivered (conditioned stimulus). During the last 5 s of the tone stimulus, a foot shock of 0.8 mA was delivered as an unconditioned stimulus through a shock generator. This procedure was repeated four to six times with 15-s intervals until the mice showed over 12-s freezing during the interval. Then 24 h after the conditioning, tone- and context-dependent tests were carried out. For the tone-dependent test, the freezing response was measured in the neutral cage for 1 min in the presence of a continuous-tone stimulus identical to the conditioned stimulus. For the context-dependent test, mice were placed in the training cage, and the freezing response was measured for 2 min in the absence of the conditioned stimulus (28).

Histochemical analysis
After completion of behavioral analyses, mice were deeply anesthetized with pentobarbital and perfused intracardially with 4% paraformaldehyde in phosphate-buffered saline (PBS). The brains were removed, post-fixed with the same fixative and cryoprotected with 30% sucrose-containing PBS. Sections (20 μm) containing hippocampus were obtained using a rotary microtome (HM505E; Microm International GmbH, Walldorf, Germany), mounted on slides and stored at −80°C until use.

Nissl staining was carried out as previously reported (21, 27). Digitized images of the Nissl-stained sections were obtained with a cooled CCD digital camera (AxioCam MRc5; Carl Zeiss GmbH, Jene, Germany) mounted on a phase-contrast microscope (Axio Imager A1, Carl Zeiss) using a 20 × magnification lens. Nissl-positive neuronal cell numbers were manually and rigidly counted within the hippocampal pyramidal cell layer (CA1 and CA3 regions) and the dentate gyrus (DG) of the scanned digital images. The total cell counts were averaged from at least three sections per animal.

Photomicrographs were taken using a microscope digital camera system (AxioCam / Axio Imager, Carl Zeiss) at 5 × magnification. To prevent variability in staining due to each experimental procedure, the brains of 4–6 mice, equated across experimental groups, were processed at the same slide using the same reagents and temperature conditions.

Measurement of uterine weight and bone mineral density
After the perfusion with 4% paraformaldehyde in PBS, the uterus was removed and weighed. The femurs were removed from the hind legs and stored in PBS containing 4% paraformaldehyde. The bone mineral density of femur was measured using a dual X-ray absorptiometer (DCS-600R; Aloka Corp., Tokyo) (21, 27).

Statistical analysis
Statistical analysis of the experimental data was carried out using Prism 5 for Mac OS X (GraphPad Software, San Diego, CA, USA). The significance of differences was determined by one- and two-way repeated measures ANOVA, followed by the Tukey’s multiple comparison test and the Bonferroni post hoc test, respectively, for multigroup comparisons. The unpaired t-test was used for two-group comparisons. The criterion for statistical significance was P < 0.05.

Results
Effect of placental extract on OVX-induced gain in body weight of mice
Female mice (weight: 28.7 ± 0.3 g, n = 49) were randomly divided into four groups: sham-operated control (n = 13), vehicle-treated OVX (n = 12), low-dose placental extract (120 mg/kg)-treated OVX (n = 12) and high-dose placental extract (2160 mg/kg)-treated OVX groups (n = 12). There was no significant difference in body weight between the four groups (P > 0.05 by one-way ANOVA). Two weeks after surgical operation, OVX mice showed a significant increase in body weight compared with the sham-operated control (196% of sham-operated controls, P < 0.001 by Tukey’s multiple comparison test) (Fig. 1). Chronic treatment with placental extract (120 and 2160 mg/kg) did not affect the OVX-induced gain in body weight (120 and 2160 mg/kg: 177% and 177% of sham-operated controls; P > 0.05 and P > 0.05 vs. OVX group by Tukey’s multiple comparison test, respectively) (Fig. 1), and a significant difference disappeared between the groups after the stress period (P > 0.05 between groups by one-way ANOVA) (data not shown).

Effect of placental extract on OVX/CS-induced impairment of conditioned fear memory in mice
We have already shown that OVX mice exposed to repeated daily restraint stress (6 h/day) for 3 weeks exhibit decreases in context- and tone-dependent freezing 24 h after fear conditioning, although the OVX or CS alone does not affect the fear memory observed in sham-operated control mice (22). Similar to the previous find-
ing (22), the OVX/CS caused decreases in context-dependent freezing (Fig. 2C, left) and tone-dependent freezing (Fig. 2C, right) 24 h after fear conditioning, compared with the sham-operated–no stress (Sham/NS) group (context and tone: 32% and 45% of Sham/NS controls; \( P < 0.01 \) and \( P < 0.001 \) by Tukey’s multiple comparison test, respectively). Chronic treatment with placental extract (120 or 2160 mg/kg) for 5 weeks significantly ameliorated the OVX/CS-induced decreases in context-dependent freezing (120 and 2160 mg/kg: 94% and 90%, \( P < 0.01 \) and \( P < 0.05 \) vs. the OVX/CS group by Tukey’s multiple comparison test, respectively) (Fig. 2C, left) and tone-dependent freezing (120 and 2160 mg/kg: 87% and 91%, \( P < 0.05 \) and \( P < 0.05 \) vs. OVX/CS group by Tukey’s multiple comparison test, respectively) (Fig. 2C, right) in mice without affecting the fear behaviors during the pre-conditioning (context and tone: \( P > 0.05 \) and \( P > 0.05 \) between groups by one-way ANOVA, respectively) (Fig. 2A) and conditioning sessions of the test (interval, \( P < 0.0001 \), group; \( P > 0.05 \), group × interval; \( P > 0.05 \) by two-way repeated measures ANOVA) (Fig. 2B).
Effect of placental extract on OVX/CS-induced neuronal cell loss in the hippocampal CA3 region of mice

Our previous study also demonstrated that the combination of OVX and repeated restraint stress decreases the neuronal cell numbers in the hippocampal CA3 region, compared with those of the other three groups: stress alone, OVX alone, and sham-operated control groups (22). Figure 3 shows typical microscopic images of the Nissl-stained hippocampal CA3 region. In agreement with the previous finding (22), the OVX/CS caused approximately 20% – 25% of Nissl-positive cell loss with corresponding decrement in cell layer thickness in the hippocampal CA3 region (Fig. 3B), compared with the Sham/NS controls (Fig. 3A). Chronic treatment with placental extract (120 and 2160 mg/kg) for 5 weeks protected against the Nissl-positive cell loss in the hippocampal CA3 region of OVX/CS mice (Fig. 3: C, D). Table 1 shows the numbers of Nissl-positive cells in the CA1 and CA3 regions and DG of the hippocampus. Chronic treatment with placental extract specifically improved the OVX/CS-induced decrease in Nissl-positive cell numbers in the CA3 region (77% of Sham/NS controls, $P < 0.01$ vs. Sham/NS group by Tukey’s multiple comparison test) to the control levels (120 and 2160 mg/kg: 95% and 98%, $P < 0.05$ and $P < 0.01$ vs. OVX/CS group by Tukey’s multiple comparison test, respectively). In contrast, chronic treatment with placental extract did not affect the Nissl-positive cell numbers in the CA1 region and DG of the hippocampus, in which the OVX/stress did not cause neuronal cell loss.

Effects of placental extract on changes in bone mineral density and uterine weight in OVX/CS mice

After behavioral analysis, bone mineral density and uterine weight were evaluated. We preliminarily determined that OVX alone caused decreases in bone mineral density and uterine weight in normal female mice and that CS did not affect the bone mineral density and uterine weight in both sham-operated and OVX mice (unpublished observation). We found that chronic treatment with 17β-estradiol improved the loss of bone mineral density and abnormally increased uterine weight in...
Table 1. Effect of placental extract on OVX/CS-induced change in Nissl-positive cell number in hippocampal CA1, CA3 regions, and dentate gyrus of mice

| Treatments                        | CA1   | CA3     | Dentate gyrus |
|----------------------------------|-------|---------|---------------|
| Sham/NS                          | 2.59 ± 0.12 | 3.77 ± 0.23 | 7.20 ± 0.49   |
| OVX/CS                           | 2.57 ± 0.12 | 2.90 ± 0.11** | 7.19 ± 0.26   |
| OVX/CS + Placental extract (120 mg/kg) | 2.79 ± 0.19 | 3.58 ± 0.11† | 7.04 ± 0.15   |
| OVX/CS + Placental extract (2160 mg/kg) | 2.75 ± 0.11 | 3.70 ± 0.15†† | 6.44 ± 0.42   |

Results are shown as means ± S.E.M. with n = 5 – 6 for each group. ** P < 0.01, significantly different from the Sham/NS group; † P < 0.05, †† P < 0.01, significantly different from the OVX/CS group; one-way ANOVA (CA1: P > 0.05, CA3: P < 0.01, dentate gyrus: P > 0.05) and post hoc Tukey’s multiple comparison test.

OVX/CS mice (22). The present study showed that the OVX/CS caused decreases in uterine weight (Fig. 4A) and bone mineral density (Fig. 4B), compared with the Sham/NS group (uterine and bone: 21% and 75% of Sham/NS controls; P < 0.001 and P < 0.001 by Tukey’s multiple comparison test, respectively). This study further demonstrated that chronic treatment with placental extract (120 and 2160 mg/kg) for 5 weeks did not affect the decreases in uterine weight (120 and 2160 mg/kg: 19% and 22%, P > 0.05 and P > 0.05 vs. OVX/CS group by Tukey’s multiple comparison test, respectively) (Fig. 4A) and bone mineral density (120 and 2160 mg/kg: 81% and 80%, P > 0.05 and P > 0.05 vs. OVX/CS group by Tukey’s multiple comparison test, respectively) (Fig. 4B) in OVX/CS mice.

Discussion

Estrogen replacement therapy has several beneficial effects, including a cognitive enhancing effect (4 – 7), in menopausal women. However, it is also known to have serious side effects including increased risk of breast and uterine cancers (29, 30). Further clinical study reported controversial results indicating a lack of efficacy of the therapy on cognition in women aged over 65 years (8). The present study was aimed to clarify how treatment with porcine placental extract influences the memory deficits and morphological changes in OVX/stress-subjected mice. We found that daily placental extract treatment attenuated fear memory impairment and hippocampal neuronal loss in OVX/stress-subjected mice, as did estrogen replacement (22). This is the first pharmacological evidence to demonstrate the neuroprotective effects of placental extract. Further, we found that treatment with placental extract did not affect the gain in body weight and decreases in bone mineral density and uterine weight in OVX mice, although estrogen replacement did have effects on them (22). We have recently reported the similar ameliorating effects of Ginkgo biloba extract EGb 761 in OVX/stress-subjected rats (27). Taken together, the present study suggests that placental extract is useful as a cognitive enhancer in postmenopausal women.

Our recent studies demonstrated that OVX over 5 weeks caused a significant increase in body weight and decreases in bone mineral density of femurs and uterine weight, compared with those of sham-operated control
Placental Extract Improves Memory Loss

rats (21, 27) and mice (22). In addition, these studies indicated that overburden of 21 days of repeated restraint stress (6 h/day) markedly decreased the numbers of hippocampal CA3 pyramidal neurons in the O VX animals, while each caused a slight decrease in cell number, and that memory impairment was only observed in the O VX/stress-subjected animals. Thus, in this study, all O VX mice received chronic stress to determine the effect of placental extract on memory deficits and neuromorphological change more simply. Moreover, in this study we examined the effects of placental extract at two doses (120 and 2160 mg/kg) on O VX/stress-induced pathophysiological changes, to assess drug efficacy and some aspects of potential toxicity. Similar to our previous finding on the effects of E Gb 761, the results of this study indicated that placental extract at doses of both 120 and 2160 mg/kg did not cause adverse side effects and attenuated the O VX/stress-induced fear memory impairment in female mice without affecting gain in body weight and decreases in bone mineral density and uterine weight. The present study also revealed that treatment with placental extract attenuated the O VX/stress-induced loss of Nissl-positive cells in the hippocampal CA3 region. To date, there is no direct evidence indicating the relationship between the hippocampal CA3 atrophy and memory loss during menopause. On the other hand, evidence-based clinical research, which reviews the systematic identification of randomized clinical trials, demonstrates that surgical menopause may be accompanied by cognitive impairment that primarily affects episodic memory (31). In addition, a growing number of animal studies indicate that the hippocampal CA3 pathology is associated with the episodic-like memory dysfunction (32 – 34). Furthermore, L uques et al. (35) have demonstrated that a selective reduction of hippocampal cholinergic innervation is associated with impairment in episodic memory, as well as in spatial learning. Taken together with our previous findings showing that the cholinesterase inhibitors donepezil and galantamine ameliorated O VX/CS-induced memory impairment (22), the present study suggests that placental extract ameliorates memory impairment in O VX/stress mice by neuroprotection in the CA3 region and further that placental extract has therapeutic efficiency against memory problems in postmenopausal women.

Placental extracts contain a variety of bioactive molecules, such as proteins, peptides, glycosaminoglycans, amino acids, RNA, and DNA, and thus all of these may contribute to the regenerating effects (36). Among them, possible molecules that may be bioactive via oral administration are unknown. It appears that the large molecular size of proteins, such as hormones, enzymes, growth factors and cytokines, makes them unlikely candidates because orally administered proteins usually undergo intestinal digestion and cannot enter the general circulation. Interestingly, Alkam et al. (37) recently reported that chronic oral treatment with Leu-Ile, a hydrophobic dipeptide, prevents the impairment of recognition memory induced by amyloid β peptide in mice. Therefore, we speculate that possible bioactive molecules via oral administration are small in molecular size, such as dipeptides, which can enter the general circulation without intestinal digestion (38, 39). Further study is required to identify such bioactive molecules from placental extracts.

On the other hand, it is well documented that placenta contains estrogens (17, 18). Estrogens are known to exert various neuromodulating actions by the expression of neurotrophins such as brain-derived neurotrophic factor (40), which affects neuronal survival, differentiation, and synaptic plasticity (41 – 43). In addition, estrogens also play a greater role in uterine responsiveness and function (44), bone formation (45), and bone remodeling (46). Therefore, the present study indicates that estrogen could not be involved in the neuroprotective effects by placental extract because the extract had no effects on bone mineral density and the weight of the uterus in O VX mice.

Through a series of studies using O VX/stress animals (21, 22, 27), we have discovered that the combination of O VX and CS is necessary in induction of hippocampal neuronal loss and memory dysfunction. That is, our findings have demonstrated that stress-related molecules may act as a mediator of neuronal loss under the estrogen-depleted condition. Glucocorticoid is well known to be secreted in response to stress, and Kim et al. (47) have revealed that glucocorticoid receptor activation by dexamethasone, a synthetic glucocorticoid receptor agonist, blocks both proliferation and differentiation in hippocampal neurogenesis. Interestingly, Tongjaroenbuangam et al. (48) have recently showed that the administration of dexamethasone causes neuronal death in the CA3 layer of the hippocampus and that okra ( Abelmoschus esculentus Linn.) extract and its derivatives, quercetin and rutin, protect the dexamethasone-induced neuronal death in mice. Taken together, these findings suggest that glucocorticoid-mediated mechanisms are responsible for hippocampal neuronal dysfunction. Thus, although further experiments are required to elucidate the precise mechanisms of neuroprotection by placental extracts, we suppose that bioactive molecules in placental extracts alleviate glucocorticoid-mediated hippocampal neuronal dysfunction.

In conclusion, the present study suggests that placental extract can attenuate neuronal loss of the hippocampal CA3 region and improve fear memory impairment in-
duced by the combination of OVX and environmental stress. Application of placental extract could thus offer an interesting approach to prevent memory problems in postmenopausal women.

Acknowledgments

We are grateful to Mr. Taichi Kaku, MS (Japan Bio Products Co., Ltd., Tokyo) for providing porcine placental extract. This study was supported in part by grants for Scientific Research (19390062) and for the 21st Century COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan and a Grant-in-Aid for Scientific Research (20590083) from the Japan Society for the Promotion of Science.

References

1. Woods NF, Mitchell ES, Adams C. Memory functioning among midlife women: observations from the Seattle Midlife Women’s Health Study. Menopause. 2000;7:257–265.
2. Lebrun CE, van der Schouw YT, de Jong FH, Pols HA, Grobbee DE, Lamberts SW. Endogenous oestrogens are related to cognition in healthy elderly women. Clin Endocrinol. 2005;63:50–55.
3. Pinkerton JV, Henderson VW. Estrogen and cognition, with a focus on Alzheimer’s disease. Semin Reprod Med. 2005;23:172–179.
4. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101:485–512.
5. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA. 2000;283:1007–1015.
6. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489–1499.
7. Genazzani AR, Pluchino N, Luisi S, Luisi M. Estrogen, cognition and female ageing. Hum Reprod Update. 2007;13:175–187.
8. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progesterin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663–2672.
9. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291:2959–2968.
10. Hernandez J, Zarnegar R, Michalopoulos GK. Characterization of the effects of human placental HGF on rat hepatocytes. J Cell Physiol. 1992;150:116–121.
11. Goldstein LD, Reynolds CP, Perez-Polo JR. Isolation of human nerve growth factor from placental tissue. Neurochem Res. 1978;3:175–183.
12. Maruo T, Matsuo H, Otani T, Mochizuki M. Role of epidermal growth factor (EGF) and its receptor in the development of the human placenta. Reprod Fertil Dev. 1995;7:1465–1470.
13. Ferriani RA, Ahmed A, Sharkey A, Smith SK. Colocalization of acidic and basic fibroblast growth factor (FGF) in human placenta and the cellular effects of bFGF in trophoblast cell line JEG-3. Growth Factors. 1994;10:259–268.
14. Han VK, Carter AM. Spatial and temporal patterns of expression of messenger RNA for insulin-like growth factors and their binding proteins in the placenta of man and laboratory animals. Placenta. 2000;21:289–305.
15. Frolik CA, Dart LL, Meyers CA, Smith DM, Sporn MB. Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A. 1983;80:3676–3680.
16. Lysiak JJ, Han VK, Lala PK. Localization of transforming growth factor α in the human placenta and decidua: role in trophoblast growth. Biol Reprod. 1993;49:885–894.
17. Tabei T. Biosynthesis of estrogens in the human placenta. Acta Obstet Gynaecol Jpn. 1970;17:1–10.
18. Simpson ER, MacDonald PC. Endocrine physiology of the placenta. Annu Rev Physiol. 1981;43:163–188.
19. Kong MH, Park SB. Effect of human placental extract on health status in elderly Koreans. Evid Based Complement Alternat Med. 2012;2012:732915.
20. Kong MH, Lee EJ, Lee SY, Cho SJ, Hong YS, Park SB. Effect of human placental extract on menopausal symptoms, fatigue, and risk factors for cardiovascular disease in middle-aged Korean women. Menopause. 2008;15:296–303.
21. Takuma K, Matsuo A, Himenoy, Hoshina Y, Ohno Y, Funatsu Y, et al. 17β-estradiol attenuates hippocampal neuronal loss and cognitive dysfunction induced by chronic restraint stress in ovariectomized rats. Neuroscience. 2007;146:60–68.
22. Takuma K, Mizoguchi H, Funatsu Y, Hoshina Y, Himeno Y, Fukuzaki E, et al. Combination of chronic stress and ovariectomy causes conditioned fear memory deficits and hippocampal cholinergic neuronal loss in mice. Neuroscience. 2012;207:261–273.
23. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–661.
24. Wu J, Yang T, Wang C, Liu Q, Yao J, Sun H, et al. Laennec protects mice from concanavalin A-induced liver injury through inhibition of inflammatory reactions and hepatocyte apoptosis. Biol Pharm Bull. 2008;31:2040–2044.
25. Gurgel LA, Santos FA, Rao VS. Effects of human placental extract on chemical and thermal nociception in mice. Eur J Pain. 2000;4:403–408.
26. Pham K, Nacher J, Hof PR, McEwen BS. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. Eur J Neurosci. 2003;17:879–886.
27. Takuma K, Hoshina Y, Arai S, Himeno Y, Matsuo A, Funatsu Y, et al. Ginkgo biloba extract EGb 761 attenuates hippocampal neuronal loss and cognitive dysfunction resulting from chronic restraint stress in ovariectomized rats. Neuroscience. 2007;149:256–262.
28. Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 2003;17:50–52.
29. Seifert M, Galid A, Kubista E. Estrogen replacement therapy in women with a history of breast cancer. Maturitas. 1999;32:63–68.
30. Sittisomwong T, Suneja A, Kudelka AP, Verschraegen CF,
Kavanagh JJ. Estrogen replacement therapy and ovarian cancer. Eur J Gynaecol Oncol. 2000;21:348–354.
31 Henderson VW, Sherwin BB. Surgical versus natural menopause: cognitive issues. Menopause. 2007;14:572–579.
32 Kesner RP, Hunsaker MR, Warthen MW. The CA3 subregion of the hippocampus is critical for episodic memory processing by means of relational encoding in rats. Behav Neurosci. 2008;122:1217–1225.
33 Daumas S, Halley H, Lassalle JM. Disruption of hippocampal CA3 network: effects on episodic-like memory processing in C57BL/6J mice. Eur J Neurosci. 2004;20:597–600.
34 Palmer A, Good M. Hippocampal synaptic activity, pattern separation and episodic-like memory: implications for mouse models of Alzheimer’s disease pathology. Biochem Soc Trans. 2011;39:902–909.
35 Luques L, Shoham S, Weinstock M. Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil. Exp Neurol. 2007;206:209–219.
36 Tonello G, Daglio M, Zaccarelli N, Sottofattori E, Mazzei M, Balbi A. Characterization and quantitation of the active polynucleotide fraction (PDRN) from human placenta, a tissue repair stimulating agent. J Pharm Biomed Anal. 1996;14:1555–1560.
37 Alkam T, Nitta A, Furukawa-Hibi Y, Niwa M, Mizoguchi H, Yamada K, et al. Oral supplementation with Leu-Ile, a hydrophobic dipeptide, prevents the impairment of memory induced by amyloid beta in mice via restraining the hyperphosphorylation of extracellular signal-regulated kinase. Behav Brain Res. 2010;210:184–190.
38 Liu KX, Kato Y, Kaku TI, Santa T, Imai K, Yagi A, et al. Hydroxyprolyserin derivatives JB923 and IBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. J Pharmacol Exp Ther. 2000;294:510–515.
39 Wu J, Wang C, Liu Q, Yang T, Zhang Q, Peng J, et al. Protective effect of JB923 on concanavalin A-induced hepatocyte toxicity on primary cultural rat hepatocytes. Eur J Pharmacol. 2008;589:299–305.
40 Solum DT, Handa RJ. Estrogen regulates the development of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus. J Neurosci. 2002;22:2650–2659.
41 Lu B, Chow A. Neurotrophins and hippocampal synaptic transmission and plasticity. J Neurosci Res. 1999;58:76–87.
42 Thoenen H. Neurotrophins and activity-dependent plasticity. Prog Brain Res. 2000;128:183–191.
43 Yamada K, Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processes. J Pharmacol Sci. 2003;91:267–270.
44 Couse JF, Hewitt SC, Bunch DO, Sar M, Walker VR, Davis BJ, et al. Postnatal sex reversal of the ovaries in mice lacking estrogen receptors α and β. Science. 1999;286:2328–2331.
45 Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson JA, Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol. 2001;171:229–236.
46 Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-β in bone remodeling in females but not in males. Bone. 2002;30:18–25.
47 Kim JB, Ju JY, Kim JH, Kim TY, Yang BH, Lee YS, et al. Dexamethasone inhibits proliferation of adult hippocampal neurogenesis in vivo and in vitro. Brain Res. 2004;1027:1–10.
48 Tongiaroebuangam W, Ruksee N, Chantiratikul P, Pakdeearong N, Kongbuntad W, Govitrapong P. Neuroprotective effects of quercetin, rutin and okra (Abelmoschus esculentus Linn.) in dexamethasone-treated mice. Neurochem Int. 2011;59:677–685.